Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 19/20 | 0.82 |
| ▸ | MET | P08581 | 12/20 | 0.82 |
| ▸ | MERTK | Q12866 | 4/20 | 0.82 |
| ▸ | FLT3 | P36888 | 2/20 | 0.82 |
| ▸ | PLK4 | O00444 | 1/20 | 0.82 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.82 |
| ▸ | RET | P07949 | 1/20 | 0.82 |
| ▸ | KDR | P35968 | 1/20 | 0.82 |
| ▸ | MST1R | Q04912 | 1/20 | 0.82 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.82 |
| ▸ | CAMK4 | Q16566 | 1/20 | 0.82 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.82 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.82 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.82 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680356 | 0.97 | AXL (0.78) | AXLMETMERTKFLT3PLK4 | |
| SCHEMBL12190617 | 0.95 | MET (0.74) | AXLMETMERTKFLT3PLK4 | |
| SCHEMBL19462918 | 0.93 | AXL (0.80) | AXLMETMERTKFLT3PLK4 | |
| SCHEMBL680261 | 0.93 | AXL (0.71) | AXLMETMERTKFLT3PLK4 | |
| SCHEMBL12190629 | 0.92 | AXL (0.69) | AXLMETMERTKFLT3PLK4 | |
| Merestinib SCHEMBL679002 | 0.90 | AXL (1.00) | AXLMETMERTKFLT3PLK4 | |
| Merestinib SCHEMBL29493094 | 0.90 | AXL (1.00) | AXLMETMERTKFLT3PLK4 | |
| Merestinib SCHEMBL680728 | 0.90 | AXL (0.99) | AXLMETMERTKFLT3PLK4 | |
| Merestinib SCHEMBL29726013 | 0.90 | AXL (0.99) | AXLMETMERTKFLT3PLK4 | |
| SCHEMBL679396 | 0.89 | AXL (0.66) | AXLMETMERTKFLT3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2310382-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | Eli Lilly & Company (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | AXL 113/4885MET 1/4885MERTK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.